КОРРЕКЦИЯ АНТИОКСИДАНТНОГО СТАТУСА ПРИ ПРИМЕНЕНИИ АТОРВАСТАТИНА У ПАЦИЕНТОВ С МЕТАБОЛИЧЕСКИМ СИНДРОМОМ

Aim. To study the changes in antioxidant status and glucose-insulin homeostasis among atorvastatin-treated patients with metabolic syndrome and to investigate the potential of coenzyme Q10 for the correction of these changes.  Material and methods. The study included 44 patients with metabolic syndrome (MS). For one year, the first group (n=21) received atorvastatin, while the second group (n=23) received atorvastatin and coenzyme Q10. The examination included the assessment of lipid and carbohydrate metabolism, lipid peroxidation system, and antioxidant status parameters.  Results. Atorvastatin suppressed antioxidant system and increased insulin resistance in patients with MS. The combination of atorvastatin and coenzyme Q10 increased antioxidant defence levels, prevented a statinnduced increase in lipid peroxidation, and did not affect carbohydrate metabolism parameters in MS patients.  Conclusion. The combination of atorvastatin and coenzyme Q10 demonstrated lipid-lowering effects, optimised lipid peroxidation processes, increased antioxidant defence levels, and minimised negative statininduced effects on glucose and insulin metabolism in MS patients.